Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2888)	8/5/2005 7:51:01 PM
From: Ian@SI	Read Replies (1) \| Respond to of 12215

Is this your kind of company? NexMed (NEXM) : Brean Murray initiates STRONG BUY. Target $4. Firm believes that corporate development will accelerate in 4Q05, bringing NexMed what is likely to be one large pharma co and one mid-level specialty pharma co as partners for NM100060 and Alprox-TD, respectively. Firm believes that Novartis (NVS), which owns the patents for terbinafine and currently sells it as Lamisil, has already tried to lock up NEXM for a six-month exclusive negotiation period during which NVS wanted to evaluate NM100060 thoroughly. Firm believes that NEXM declined the exclusive request because it is also far along in discussions with several other potential large pharma partners.

To: scaram(o)uche who wrote (2888)	8/10/2005 9:44:07 AM
From: scaram(o)uche	Read Replies (4) \| Respond to of 12215

>> The Peter (Biomaven) Principle and KOSN << Nope, not an example. Didn't hold. For those who don't know "Peter's Principle", it's sorta like Groundhog's Day for Biotech...... if a company rallies on dilution...... if investors are overjoyed that the company has more money to apply to its great pipeline? And if this phenomenon is observed a few times, clustering in time? Seven more weeks of biotech rally. :-) edit: sorta same vein........ Message 21589468